AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Convatec Group PLC

Director's Dealing Dec 18, 2018

4959_dirs_2018-12-18_729638bc-cde5-4a3c-b4af-6b8eff84bc5c.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8615K

ConvaTec Group PLC

18 December 2018

18 December 2018

ConvaTec Group Plc

("ConvaTec" or "the Company")

Director/PDMR Shareholding

The Company announces the following change in the interests of a Director in ordinary shares of 10 pence each in the share capital of the Company ("Shares").

The Company announces that on 14 December 2018, Frank Schulkes, the Company's Chief Financial Officer, was granted a conditional share award, comprising 221,619 Shares under the Company's Long Term Incentive Plan (LTIP), subject to a time vesting period of three years, performance conditions based on a combination of relative total shareholder return, earnings per share and return on invested capital over the three-year period equally weighted, and continued employment.

The number of Shares are the maximum available if the performance conditions for the three year performance period are fully satisfied. Further details of the LTIP and performance conditions will be contained in the Company's next Annual Report.

No consideration was paid for the grant of this award.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Frank Schulkes
2 Reason for the notification
a) Position/Status Chief Financial Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name ConvaTec Group Plc
b) LEI 213800LS272L4FIDOH92
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code
Ordinary shares of 10p each in ConvaTec Group Plc ("Shares")

GB00BD3VFW73
b) Nature of the transaction Grant of conditional share award under the ConvaTec Group Plc Long Term Incentive Plan subject to Long Term Incentive Plan, subject to (i) time vesting period of three years (ii) performance conditions based on a combination of relative total shareholder return, earnings per share and return on invested capital over three year period, equally weighted (iii) continued employment
c) Price(s) and volume(s) Exercise price(s)

N/A
Volume granted:

  221,619
d) Aggregated information

- Aggregated volume 

- Price
N/A
e) Date of the transaction 2018-12-14
f) Place of the transaction Outside a trading venue

Enquiries

Media

Bobby Leach, VP Group Corporate Affairs, ConvaTec                        +44 (0)7770 842 226

Alastair Elwen, Finsbury                                                                       +44 (0)207 251 3801

Analysts and Investors

John Crosse, VP Investor Relations, ConvaTec                                    +44 (0)7500 141 435

Kirsty Law, Director Investor Relations, ConvaTec                             +44 (0)7470 909 582

[email protected]

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHLLFVVFALTLIT

Talk to a Data Expert

Have a question? We'll get back to you promptly.